Xenon Pharmaceuticals Inc. (XENE)

40.31 -1.32 (-3.17%) At close: 04:00PM EDT

Xenon Pharmaceuticals Inc.

3650 Gilmore Way
Suite 200
Burnaby, BC V5G 4W8
Canada
604 484 3300
https://www.xenon-pharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 251

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.	President, CEO & Director	973.76k	N/A	1976
Ms. Sherry Aulin	Chief Financial Officer	3.03M	607.7k	1984
Ms. Andrea DiFabio J.D.	Chief Legal Officer & Corporate Secretary	200.51k	N/A	1968
Dr. Christopher E. Von Seggern M.B.A., M.P.H., M.P.H. M.B.A, Ph.D.	Chief Commercial Officer	618.07k	N/A	1979
Dr. Christopher John Kenney M.D.	Chief Medical Officer	684.22k	N/A	1971
Ms. Shelley McCloskey B.A.	Executive Vice President of Human Resources	N/A	N/A	1960
Dr. Robin P. Sherrington Ph.D.	Executive Vice President of Strategy & Innovation	351.67k	N/A	1961
Dr. James R. Empfield Ph.D.	Executive Vice President of Drug Discovery	323.43k	N/A	1961
Ms. Sheila M. Grant M.B.A., M.Sc., MBA	Executive Vice President of R&D Operations	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

Corporate Governance

Xenon Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.